Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_4
2
33%
Ph not_applicable
1
17%
Ph phase_1
1
17%
Ph phase_3
2
33%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
2(33.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 32 (33.3%)
Phase 42 (33.3%)
N/A1 (16.7%)

Trials by Status

completed583%
terminated117%

Recent Activity

Clinical Trials (6)

Drug Details

Intervention Type
DRUG
Total Trials
6